SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Care-plan review) — Franklin D. Roosevelt — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientFranklin D. Roosevelt
Date of birth1882-01-30
IdentifiersMRN HR-ET002-SYN-TD; SSN (made up) 000-02-5130
Document date1944-09-25
AuthorNathaniel Brooks, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-month heart failure review with repeat echocardiogram. [S]

History of Present Illness

Mr. Roosevelt returns for his six-month review and repeat echocardiogram. The stomach illness in July settled within four days; he restarted his heart failure medicines on the third day without lightheadedness, and his weight is back to 82 kg. He is finishing an adapted cardiac rehabilitation program of seated arm-cycle and resistance-band training and will keep up the band exercises at home three times a week. He propels his wheelchair on level ground and up short ramps without breathlessness, sleeps on one pillow, and has had no leg swelling since furosemide stopped. His home blood pressures run 115 to 125 systolic, and he has had no lightheadedness on transfers. He has not smoked since April. He prefers not to raise his medicine doses further for now, because safe transfers matter more to him than small further gains, and the July illness showed how quickly his blood pressure can fall. [S]

ElementDetail
Interval changeJuly gastroenteritis resolved in four days; medicines restarted on the third day
FunctionLevel ground and short ramps without breathlessness; finishing cardiac rehabilitation
Weight logBack to 82 kg; no swelling off furosemide
Home blood pressure115 to 125 systolic
TobaccoNo cigarettes since April
Patient preferenceNo further dose increases for now, to protect safe transfers
NYHA classI to II

Review of Systems

SystemResultFinding
ConstitutionalNegativeGood energy; weight stable
CardiovascularNegativeNo chest pain, palpitations, orthopnea, or leg swelling
RespiratoryNegativeNo breathlessness on level ground or short ramps
GastrointestinalNegativeBowel habit back to his usual since July
NeurologicalNegativeNo lightheadedness on transfers
MusculoskeletalNegativeNo muscle aches; no shoulder pain with rehabilitation exercise

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet by mouth twice dailyOne tablet by mouth twice dailyOral route1944-03-27 to 1944-04-10completedS
Sacubitril 49 mg / valsartan 51 mg oral tablet, one tablet by mouth twice dailyOne tablet by mouth twice dailyOral route1944-04-10activeS
Carvedilol 3.125 mg oral tablet, one tablet by mouth twice daily with foodOne tablet by mouth twice daily with foodOral route1944-03-27 to 1944-04-10completedS
Carvedilol 6.25 mg oral tablet, one tablet by mouth twice daily with foodOne tablet by mouth twice daily with foodOral route1944-04-10 to 1944-06-26completedS
Carvedilol 12.5 mg oral tablet, one tablet by mouth twice daily with foodOne tablet by mouth twice daily with foodOral route1944-06-26activeS
Spironolactone 25 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1944-04-10activeS
Empagliflozin 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1944-03-27activeS
Furosemide 20 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1944-03-27 to 1944-06-26completedS
Atorvastatin 40 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1944-03-27activeS
Nicotine 21 mg/24 hr transdermal patch, apply one patch dailyApply one patch to the skin dailyTopical route1944-03-27 to 1944-06-26completedS
Ferric carboxymaltose 750 mg in 15 mL intravenous infusion, two doses one week apart750 mg intravenously, two doses one week apartIntravenous route1944-04-10 to 1944-04-17completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1944-09-25Body height188cmS
1944-09-25Body weight82kgS
1944-09-25Body mass index (BMI) [Ratio]23.2kg/m2S
1944-09-25Systolic blood pressure122mm[Hg]S
1944-09-25Diastolic blood pressure76mm[Hg]S
1944-09-25Heart rate64/minS
1944-09-25Respiratory rate14/minS
1944-09-25Body temperature36.7CelS
1944-09-25Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1944-09-25Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma410pg/mL<=125 pg/mLHighS
1944-09-25Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
1944-09-25Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
1944-09-25Creatinine [Mass/volume] in Serum or Plasma1.21mg/dL0.74-1.35 mg/dLNormalS
1944-09-25Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1939)/1.73 sq M68mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1944-09-25Glucose [Mass/volume] in Serum or Plasma95mg/dL70-99 mg/dLNormalS
1944-09-25Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation68mg/dL<=99 mg/dLNormalS
1944-09-25Albumin/Creatinine [Mass Ratio] in Urine22mg/g<=30 mg/gNormalS
1944-09-25Left ventricular Ejection fraction45%50-70%LowS
1944-09-25Overall summary score [KCCQ-12]78{score}S

Physical Exam

Vital signs recorded on 1944-09-25; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 82 kg on the wheelchair scale
NeckJugular venous pressure 6 cm
LungsClear
HeartRegular rhythm, rate 64; no S3
ExtremitiesNo edema; dorsalis pedis and posterior tibial pulses palpable in both feet

Problems

ProblemClinical statusVerificationCodeProvenance
Hypertensive heart disease with heart failure; synthetic modern diagnosis linked to the documented 1862 findingsactiveconfirmed I11.0S — Synthetic active diagnosis for the teaching episode; the 1944 findings remain D.
Heart failure with reduced ejection fraction, NYHA class III at diagnosisactiveconfirmed I50.22S — Synthetic diagnosis confirmed by echocardiogram in the modern episode.
Nicotine dependence, cigarettesactiveconfirmed F17.210S — Synthetic modern diagnosis linked to documented cigarette smoking.
Iron deficiency anemia in heart failure, repleted with intravenous ironresolvedconfirmed D50.9S — Synthetic finding that echoes the documented 1941 anemia; the modern values are S.
Paraplegia from a paralytic illness at age 39, historically diagnosed as poliomyelitis; cause retrospectively disputedactiveprovisional B91S — Synthetic modern coding of the documented diagnosis; the alternative cause remains R.
Prediabetesactiveconfirmed R73.03S — Synthetic finding from the baseline HbA1c.
Hyperlipidemiaactiveconfirmed E78.5S — Synthetic finding from the baseline LDL cholesterol.
Acute viral gastroenteritis with mild volume depletion, resolved with oral rehydration and a short hold of heart failure medicinesresolvedconfirmed A08.4S — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBasic metabolic panelEvery 3 to 6 months when stableCompleted todayPotassium 4.5, creatinine 1.21 mg/dL, eGFR 68; back to baseline after creatinine 1.42 at the July sick visit
LaboratoryBasic metabolic panel after stopping furosemide in June1 to 2 weeks after a diuretic changeDeferredNot drawn in the window, a deviation from the protocol. The next panel was at the July sick visit, about four and a half weeks later, with potassium 4.9 during volume depletion; today's potassium is 4.5, so no harm resulted. This is the second missed post-change check this year; the corrective action is the dated laboratory appointment at every medication change
LaboratoryBasic metabolic panel after restarting the medicines held in July1 to 2 weeks after restarting sacubitril/valsartan, spironolactone, and empagliflozinDeferredThe sick-visit plan moved the recheck to today; strictly, the protocol calls for a panel within two weeks of a restart, so this is recorded as a deviation. Today's potassium and creatinine are at baseline, so no harm resulted. Corrective action: a panel one to two weeks after any future sick-day restart
LaboratoryMagnesiumWith each basic metabolic panelDeferredNot measured with any panel since diagnosis, a deviation from the protocol. He has had no arrhythmia or cramps and has been off the loop diuretic since June, so the risk of low magnesium is small. Corrective action: added to the three-month panel
LaboratoryNT-proBNPSelectively in outpatient follow-upCompleted today410 pg/mL, down from 2850; supports prognosis and decongestion
ImagingTransthoracic echocardiogram3 to 6 months after therapy is optimizedCompleted todayEjection fraction 45 percent, up from 30: heart failure with improved ejection fraction. No device therapy is indicated, and routine repeat imaging is not recommended
Imaging12-lead ECGAt initial evaluation; repeat with device considerationDeferredStill not on file, a deviation carried from April. No device decision is needed now that the ejection fraction is 45 percent, and his rhythm is regular, so no harm has resulted. Corrective action: ECG at the three-month review
ExaminationBlood pressure, heart rate, weight, jugular venous pressure, edema, lungsEvery visit; every 3 to 6 months when stableCompleted todayEuvolemic at 82 kg
SurveyNYHA functional classEvery visitCompleted todayClass I to II
SurveyKCCQ-12Every 3 to 6 monthsCompleted today78, up 40 points from baseline
SurveyDepression screen (PHQ-2)PeriodicallyDueScore 0 in June; repeat at next month's preventive visit
ReferralCardiac rehabilitationPeriodic review of participation and exercise capacityUp to dateFinishing the adapted program; home resistance-band exercise three times a week to follow
Medication safetyDose review of guideline-directed therapyEach visit while titratingCompleted todaySacubitril/valsartan and carvedilol remain below target doses by shared decision, to protect transfer safety; revisit at the three-month review
LaboratoryLipid panel4 to 12 weeks after starting a statin; then yearlyCompleted todayLDL cholesterol 68 mg/dL, a 48 percent fall, below 70 mg/dL. Drawn 26 weeks after the start, outside the window (deviation recorded in June); the response is adequate, so no harm resulted
LaboratoryLipoprotein(a)Once in adulthoodDueNot yet measured; add to the next laboratory tests
LaboratoryUrine albumin-creatinine ratioYearly in hypertensionCompleted today22 mg/g, down from 64; now normal
LaboratoryHbA1c for prediabetesYearlyUp to date5.9 percent at diagnosis; glucose 95 mg/dL today
LaboratoryHemoglobin and iron studiesYearly in heart failure with reduced or improved ejection fractionUp to dateRepleted in June
ExaminationFunduscopic examinationYearly in chronic hypertensionDueLast eye examination more than two years ago; to be arranged at next month's preventive visit
ExaminationPeripheral pulses and ankle-brachial indexEvery 2 to 3 years with a smoking historyDueFoot pulses palpable today; ankle-brachial index not yet done and due within the interval
Survey10-year ASCVD risk estimateYearly in hypertensionNot indicatedNot calculated: he already takes a statin for his LDL cholesterol and hypertensive heart disease, so the estimate would not change treatment
Medication safetyTobacco useEvery visitCompleted todayAbstinent since April
Medication safetyInfluenza vaccineEvery seasonDuePlanned at next month's preventive visit
Self-managementHome blood pressure and daily weight log; low-sodium dietEvery visitCompleted todayLog reviewed; weights stable without furosemide

Goal progress:

Guideline basis: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, heart failure and hypertension monographs (2026); Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021); USPSTF A and B Recommendations (2026)

Follow-up: Preventive visit next month. Heart failure review in three months with a basic metabolic panel with magnesium, an ECG, the KCCQ-12, and a decision on dose increases. Next scheduled visit 1944-10-23: periodic adult preventive visit. [S]